Biologics
Adicet Wins Fast Track for Lupus Cell Therapy
FDA has granted Adicet Bio a fast-track designation for ADI-001 and its use in treating adult patients with refractory systemic lupus erythematosus (SLE) with extrarenal involvement. ADI-001 is described as an investigational allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy targeting CD20 for treating autoimmune